{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:39:49Z","timestamp":1792773589279,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeOne Medicines Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108362","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:46:49Z","timestamp":1787860009000},"page":"108362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score \u22655%: a post hoc, exploratory, long-term follow-up of RATIONALE-306\u2606"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"D.","family":"Tougeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-6021","authenticated-orcid":false,"given":"J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"K.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wyrwicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-3813","authenticated-orcid":false,"given":"P.","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pazo-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4802-0727","authenticated-orcid":false,"given":"J.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-3487","authenticated-orcid":false,"given":"H.H.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108362_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108362_bib2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108362_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104134","article-title":"ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma","volume":"10","author":"Obermannov\u00e1","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108362_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14740\/wjon1254","article-title":"Esophageal cancer: an updated Surveillance Epidemiology and End Results database analysis","volume":"11","author":"Then","year":"2020","journal-title":"World J Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108362_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108362_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108362_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108362_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"10302","key":"10.1016\/j.esmoop.2026.108362_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108362_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108362_bib11","unstructured":"TEVIMBRA\u2122 (tislelizumab-jsgr) injection, for intravenous use [prescribing information]. San Mateo, CA: BeiGene, Ltd; 2024. Available at: https:\/\/d1svrc2qog2gh9.cloudfront.net\/d9104404-63d1-4d9d-b748-eaca79f7e282\/9a4dd4ce-116a-43c7-852b-65996defe155\/9a4dd4ce-116a-43c7-852b-65996defe155_source__v.pdf. Accessed August 11, 2026."},{"issue":"1","key":"10.1016\/j.esmoop.2026.108362_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108362_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108362_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100793","article-title":"Concordance between the PD-L1 Tumor Area Positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab","volume":"38","author":"Moehler","year":"2025","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108362_bib17","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s12325-025-03115-9","article-title":"First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-306","volume":"42","author":"Xu","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.esmoop.2026.108362_bib18","unstructured":"OPDIVO\u00ae (nivolumab) injection, for intravenous use [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2014. Available at: https:\/\/www.bms.com\/assets\/packageinserts\/pi\/pi_opdivo.pdf. Accessed August 11, 2026."},{"key":"10.1016\/j.esmoop.2026.108362_bib19","unstructured":"KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2024. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed August 11, 2026."},{"issue":"1","key":"10.1016\/j.esmoop.2026.108362_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108362_bib21","first-page":"188","article-title":"Patient-reported outcomes in oncology drug labeling in the United States: a framework for navigating early challenges","volume":"9","author":"Shields","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108362_bib22","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1111\/j.1524-4733.2007.00273.x","article-title":"Mayo\/FDA Patient-Reported Outcomes Consensus Meeting Group. Analysis and interpretation of results based on patient-reported outcomes","volume":"10","author":"Sloan","year":"2007","journal-title":"Value Health"},{"issue":"16_suppl","key":"10.1016\/j.esmoop.2026.108362_bib23","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2024.42.16_suppl.4032","article-title":"Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced\/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up","volume":"42","author":"Yoon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108362_bib24","doi-asserted-by":"crossref","first-page":"e1324","DOI":"10.1093\/oncolo\/oyae087","article-title":"Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer","volume":"29","author":"Mansoor","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108362_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100843","article-title":"Efficacy and safety of anti-PD-(L)1 treatments: a systematic review and meta-analysis of Asian vs non-Asian patients with esophageal squamous cell carcinoma","volume":"5","author":"Ajani","year":"2025","journal-title":"Gastro Hep Adv"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:39:58Z","timestamp":1792769998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926023057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926023057"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108362","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score \u22655%: a post hoc, exploratory, long-term follow-up of RATIONALE-306\u2606","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108362"}}